PaulJSabbatiniMD

Gynecologic Cancer, Hematologic Oncology

Professor of Medicine, Cornell University-Weill Medical College, Deputy Physician-In-Chief for Clinical Research, Memorial Sloan Kettering Cancer Center

Request Appointment

Overview of Dr. Sabbatini

Dr. Paul Sabbatini is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. He received his medical degree from University of Mississippi School of Medicine and has been in practice 28 years. Dr. Sabbatini accepts several types of health insurance, listed below. He is one of 465 doctors at Memorial Sloan Kettering Cancer Center and one of 88 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
Memorial Sloan Kettering Cancer Center New York
1275 York Avenue
New York, NY 10021
Book by Phone+1(678) 792-0595
Is this information wrong?

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1994 - 1997
Vanderbilt University Medical CenterResidency, Internal Medicine, 1989 - 1993
University of Mississippi School of MedicineClass of 1989

Certifications & Licensure

FL State Medical License 2021 - Present
NY State Medical License 1994 - 2026
NJ State Medical License 2020 - 2025
TN State Medical License 1990 - 1995
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors: New York Metro Area Castle Connolly, 2011-2014
New York Magazine: Top Doctors Castle Connolly, 2012, 2014

Clinical Trials

Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1998 Jan 01
Completed
Phase 1
Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Recurrent, Advanced, or Metastatic Endometrial Cancer Start of enrollment: 1998 Nov 01
Completed
Phase 2
Capecitabine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 1998 Dec 01
Completed
Phase 2
Vaccine Therapy in Treating Patients With Ovarian, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2000 Feb 01
Completed
Phase 1
Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer Start of enrollment: 2000 Jun 01
Completed
Phase 2
Bicalutamide and Goserelin in Treating Patients With Cancer of the Ovary, Fallopian Tube, or Peritoneum Start of enrollment: 2000 Sep 01
Completed
Phase 2
CT-2103 in Treating Patients With Recurrent Ovarian Epithelial or Fallopian Tube Cancer or Primary Peritoneal Cancer Start of enrollment: 2001 Feb 01
Completed
Phase 1, Phase 2
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2001 Mar 01
Completed
Phase 1
CT-2103 in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer or Primary Peritoneal Cancer Start of enrollment: 2002 Sep 01
Completed
Phase 2
Monoclonal Antibody Vaccine Therapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer Start of enrollment: 2002 Dec 01
Completed
Phase 1
Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian Cancer Patients Start of enrollment: 2006 Dec 01
Terminated
Phase 2, Phase 3
Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Start of enrollment: 2007 Dec 06
Active, not recruiting
Phase 3
Phase 1 Study of NY-ESO-1 Overlapping Peptides in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2008 Mar 01
Completed
Phase 1
Vaccine Therapy and OPT-821 or OPT-821 Alone in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer in Complete Remission
Withdrawn
Phase 3
OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Start of enrollment: 2010 Jul 01
Completed
Phase 2
Polyvalent Vaccine-KLH Conjugate + Opt-821 Given in Combination With Bevacizumab Start of enrollment: 2010 Oct 01
Completed
Not Applicable
Unimolecular Pentavalent (Globo-H-GM2-sTn-TF-Tn) Immunization of Patients With Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in First Remission Start of enrollment: 2010 Nov 01
Completed
Phase 1
Join now to see all

Publications & Presentations

PubMed

8 citations
Quantifying the Expanding Landscape of Clinical Actionability for Patients with Cancer.
Arcila, M. E., Arcila, M. E., Arcila, M. E., Arcila, M. E., Suehnholz, S., Nissan, M., Zhang, H., Kundra, R., Nandakumar, S., Lu, C., Carrero, S., Dhaneshwar, A., Fern...> ;Cancer Discovery. 2024 Jan 12
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival.
Kahn, R., Selenica, P., Boerner, T., Roche, K., Xiao, Y., Sia, T., Maio, A., Kemel, Y., Sheehan, M., Salo-Mullen, E., Breen, K., Zhou, Q., Iasonos, A., Grisham, R., O'...> ;Gynecologic Oncology. 2024 Jan 1
Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study.
Aaron M Praiss, Austin Miller, Judith Smith, Stuart M Lichtman, Michael Bookman, Carol Aghajanian, Paul Sabbatini, Floor Backes, David E Cohn, Peter Argenta, Michael F...> ;Gynecologic Oncology. 2023 Jul 1
1 citations
Association of patient activity bio-profiles with health-related quality of life in patients with newly diagnosed multiple myeloma: a prospective observational cohort ...
Neha Korde, Elizabet Tavitian, Donna Mastey, Joseph Lengfellner, Gil Hevroni, Andrew Zarski, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Eric L Smith, Malin Hultcra...> ;Eclinicalmedicine. 2023 Mar 1
Digitalizing the Clinical Research Informed Consent Process: Assessing the Participant Experience in Comparison With Traditional Paper-Based Methods.
Michael T Buckley, Molly R O'Shea, Sangeeta Kundu, Allison Lipitz-Snyderman, Gilad Kuperman, Suken Shah, Alexia Iasonos, Collette Houston, Stephanie L Terzulli, Joseph...> ;JCO Oncology Practice. 2023 Mar 1
7 citations
Clinical Trial Participation Among Older Adult Medicare Fee-for-Service Beneficiaries With Cancer.
Angela K Green, Sara M Tabatabai, Carol Aghajanian, Ola Landgren, Gregory J Riely, Paul Sabbatini, Peter B Bach, Colin B Begg, Allison Lipitz-Snyderman, Sham Mailankody> ;JAMA Oncology. 2022 Dec 1
3 citations
Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis.
Sushmita Gordhandas, Brooke A Schlappe, Qin Zhou, Alexia Iasonos, Mario M Leitao Jr, Kay J Park, Louise de Brot, Kaled M Alektiar, Paul J Sabbatini, Carol A Aghajanian...> ;Gynecologic Oncology Reports. 2022 Oct 1
4 citations
Long-term outcomes of patients with recurrent ovarian cancer treated with a polyvalent vaccine with bevacizumab combination.
Ryan M Kahn, Govind Ragupathi, Qin C Zhou, Alexia Iasonos, Sara Kravetz, Martee L Hensley, Jason A Konner, Vicky Makker, William P Tew, Carol Aghajanian, Paul J Sabbat...> ;Cancer Immunology, Immunotherapy. 2023 Jan 1
1 citations
One committee to review it all: A single, multi-disciplinary COVID-19 research committee.
Jocelyn Migliacci, Ann Rodavitch, Gregory Riely, Paul Sabbatini, Collette Houston, Sara Hanley> ;Contemporary Clinical Trials. 2022 Jun 1
3 citations
Validation of a Population-Based Data Source to Examine National Cancer Clinical Trial Participation.
Angela K Green, Sara M Tabatabai, Xing Bai, Akriti Mishra Meza, Anne-Marie Lesny, Carol Aghajanian, Ola Landgren, Gregory J Riely, Paul Sabbatini, Andrew Salner, Scott...> ;JAMA Network Open. 2022 Mar 1
4 citations
Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer.
, , , , , , , , , , , , , , , > ;Gynecologic Oncology. 2021 Nov 8
3 citations
Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer.
Chrisann Kyi, Ekaterina Doubrovina, Qin Zhou, Sara Kravetz, Alexia Iasonos, Carol Aghajanian, Paul Sabbatini, David R. Spriggs, Richard J. O'Reilly, Roisin E. O'Cearbh...> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
1 citations
Translating inspiration from COVID-19 vaccine trials to innovations in clinical cancer research.
Noura J. Choudhury, Gregory J. Riely, Paul Sabbatini, Matthew D. Hellmann> ;Cancer Cell. 2021 Jul 12
37 citations
OncoTree: A Cancer Classification System for Precision Oncology.
Ritika Kundra, Hongxin Zhang, Robert L. Sheridan, Sahussapont Joseph Sirintrapun, Avery Wang, Angelica Ochoa, Manda Wilson, Benjamin Gross, Yichao Sun, Ramyasree Madup...> ;JCO Clinical Cancer Informatics. 2021 Feb 1
6 citations
Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer
Emeline M. Aviki, Jessica A. Lavery, Kara Long Roche, Renee A. Cowan, Kimberly Dessources, Derman Basaran, Angela K Green, Carol Aghajanian, Roisin E. O'Cearbhaill, El...> ;Gynecologic Oncology. 2020 Aug 16
4 citations
Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy.
Julia L. Boland, Qin Zhou, Alexia Iasonos, Roisin E. O'Cearbhaill, Jason A. Konner, Margaret K. Callahan, Claire F. Friedman, Carol Aghajanian, Paul Sabbatini, Dmitriy...> ;Gynecologic Oncology. 2020 Aug 1
2 citations
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancer
Karen Cadoo, Rachel N. Grisham, Roisin E. O'Cearbhaill, Nicole N. Boucicaut, Melissa Henson, Alexia Iasonos, Qin Zhou, Debra M. Sarasohn, Jacqueline Gallagher, Sara Kr...> ;Gynecologic Oncology. 2020 Apr 1
34 citations
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway
Maria M. Rubinstein, David M. Hyman, Imogen Caird, Helen Won, Krysten Soldan, Kenneth Seier, Alexia Iasonos, William P. Tew, Roisin E. O'Cearbhaill, Rachel N. Grisham,...> ;Cancer. 2020 Mar 15
16 citations
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, f...
Roisin E. O'Cearbhaill, Wei Deng, Lee-may Chen, Joseph A. Lucci, Kian Behbakht, Nick M. Spirtos, Carolyn Y. Muller, Benedict B. Benigno, Matthew A. Powell, Emily Berry...> ;Gynecologic Oncology. 2019 Dec 1
3 citations
Engaging Community-Based Cancer Physicians: Experience of the Memorial Sloan Kettering Cancer Center Cancer Alliance.
Allison Lipitz-Snyderman, Jessica Kennington, Brooke Hogan, Deborah Korenstein, Leonard Kalman, Suresh G. Nair Md, Peter Yu, Paul Sabbatini, David G. Pfister> ;Journal of the National Comprehensive Cancer Network. 2019 Sep 1
62 citations
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
Kathleen N. Moore, Camille C. Gunderson, Paul Sabbatini, D. Scott McMeekin, Gina Mantia-Smaldone, Robert A. Burger, Mark A. Morgan, Ann M. Kapoun, Rainer Karl Brachman...> ;Gynecologic Oncology. 2019 Aug 1
88 citations
Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer
Tara Soumerai, Mark T.A. Donoghue, Chaitanya Bandlamudi, Preethi Srinivasan, Matthew T. Chang, Dmitriy Zamarin, Karen Cadoo, Rachel N. Grisham, Roisin E. O'Cearbhaill,...> ;Clinical Cancer Research. 2018 Dec 1
32 citations
Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade.
Julia L. Boland, Qin Zhou, Madhuri Martin, Margaret K. Callahan, Jason A. Konner, Roisin E. O'Cearbhaill, Claire F. Friedman, William P. Tew, Vicky Makker, Rachel N. G...> ;Gynecologic Oncology. 2019 Feb 1
4 citations
A Randomized Trial of Prophylactic Extended Carboplatin Infusion to Reduce Hypersensitivity Reactions in Recurrent Ovarian Cancer.
Katherine LaVigne, David M. Hyman, Qin C. Zhou, Alexia Iasonos, William P. Tew, Carol Aghajanian, Vicky Makker, Martee L. Hensley, Jason A. Konner, Rachel N. Grisham, ...> ;International Journal of Gynecological Cancer. 2018 Jun 1
867 citations
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients.
Ahmet Zehir, Ryma Benayed, Ronak H Shah, Aijazuddin Syed, Sumit Middha, Hyunjae R Kim, Preethi Srinivasan, Jianjiong Gao, Debyani Chakravarty, Sean M Devlin, Matthew D...> ;Nature Medicine. 2017 Jun 1
Join now to see all

Journal Articles

A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian Cancer
Karen A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology

Press Mentions

University of Mississippi Medical Center: People of the U: Paul SabbatiniSeptember 14th, 2021
How Cancer Clinical Trials Have Changed During the PandemicJune 16th, 2020
Miami Cancer Institute Has 55 Clinical Trials OngoingFebruary 27th, 2018
Join now to see all

Hospital Affiliations

Memorial Sloan Kettering Cancer CenterNew York, New York
Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey

Insurance Accepted

Aetna Choice POS II
Aetna HMO
BCBS Blue Card PPO
BCBS Illinois PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Empire BCBS HMO
Empire BCBS PPO
GHI PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
WEA Trust Preferred Provider Plan - Trust Pref
Please verify your coverage with the provider's office directly when scheduling an appointment